First-generation BCR-ABL inhibitors are not associated with significant cardiotoxic effects [70,71], while second- and third-generation BCR-ABL inhibitors such as dasatinib can cause group 1 pulmonary hypertension and HF [72,73]. The gene discussed is ABL1; the disease is pulmonary arterial hypertension.